GILD · News · 20260905N

Revenue Performance and Mix

GILEAD SCIENCES, INC. · 2026-09-05 · Importance 30 · Surprise 22

Gilead reported second-quarter revenue of approximately $7.80 billion, up 10.6% year over year and above analyst expectations. The company nevertheless reported a net loss of $6.75 per share for the quarter. Reports attributed growth to Gilead’s HIV franchise, PrEP demand, Trodelvy, and Livdelzi, although HIV remains a significant revenue-concentration risk.

Key facts